AlphaCore Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

AlphaCore Capital’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$466K	Buy	+924	New	+$488K	0.01%	857

Other funds holding MDGL

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

EULAV Asset Management Sarasota, Florida $2.77B AUM 18.47% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

AlphaCore Capital's MDGL Position: Q3 2026 in Review

AlphaCore Capital opened a new position in Madrigal Pharmaceuticals (MDGL) in Q3 2026: 924 shares worth $466K. The stake represents 0.01% of the portfolio and ranks #857 among its holdings.

180 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

AlphaCore Capital held 924 shares of Madrigal Pharmaceuticals worth $466K as of Q3 2026.
Madrigal Pharmaceuticals was a new AlphaCore Capital position in Q3 2026.
Madrigal Pharmaceuticals made up 0.01% of AlphaCore Capital's portfolio in Q3 2026, its #857 holding.
180 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on AlphaCore Capital's 13F filing for Q3 2026, filed 4 Nov 2026.